NEW YORK (GenomeWeb News) – Dutch molecular diagnostics firm Kreatech Diagnostics said it has entered into an exclusive licensing agreement providing it access to Veridex's Repeat-Free technology for the production and distribution of FISH and CISH DNA screening solutions.
In a statement, the company noted that the agreement now moves Kreatech directly into the US market. The worldwide FISH, or fluorescence in situ hybridization, and CISH, or chromogenic in situ hybridization, market is more than $150 million, and the US is the single largest market for FISH probes, Kreatech said. The company is already focused on growing that business in Europe, and the agreement "will be utilized to boost Kreatech's position as a reliable supplier of a broad commercial portfolio of molecular diagnostics used by cytogenetic labs worldwide," said Kreatech CEO Kees Moonen.
Kreatech intends on partnering with "experienced players in the field of molecular diagnostics" to increase its US market presence, the company said.
Terms of the deal were not disclosed.
Veridex's Repeat-Free technology eliminates the need for Cot-1, or blocking DNA, which results in less background and a brighter signal, "important features of FISH as a diagnostic and research tool," Kreatech said.